{"url_path":"/sec/hrmy/8-k/2026-07-16/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1802665/0001104659-26-084095-index.html","accession_number":"0001104659-26-084095","cik":"0001802665","ticker":"HRMY","issuer_name":"Harmony Biosciences Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1802665/0001104659-26-084095-index.html","primary_entity_key":"0001802665","primary_entity_name":"Harmony Biosciences Holdings, Inc."},"word_count":71,"has_tables":true,"body_markdown":"**Item 2.02.    Results of Operations and Financial Condition.**\n\n**      **On July 16, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary net product revenue for the second quarter of 2026. In addition, the Company reaffirmed its guidance related to 2026 net product revenue. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference."}